What is Theravance Biopharma's stock symbol?
Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
Where is Theravance Biopharma's stock going? Where will Theravance Biopharma's stock price be in 2017?
7 brokerages have issued 12-month price objectives for Theravance Biopharma's stock. Their forecasts range from $24.00 to $42.00. On average, they expect Theravance Biopharma's share price to reach $36.67 in the next year.
When will Theravance Biopharma announce their earnings?
Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
What are analysts saying about Theravance Biopharma stock?
Here are some recent quotes from research analysts about Theravance Biopharma stock:
According to Zacks Investment Research, "Theravance’s sole marketed product, Vibativ, continues to perform well, contributing meaningfully to the top line at the company. However, Vibativ witnessed a sequential decline due to seasonality and trends in surgical admissions. Nevertheless, the company’s efforts on the commercialization of Vibativ are encouraging. We are also positive on its efforts to expand the drug’s label, which if approved for additional indications, would be commercially significant. Further, its collaboration agreement with Mylan for revefenacin, a key late-stage pipeline candidate, is a big positive. Theravance’s progress with the rest of the pipeline is also impressive. Shares of the company have significantly outperformed the Medical-Drugs industry in 2016. Moreover, estimates have gone up ahead of the release of the company’s fourth-quarter 2016 results. However, Theravance’s heavy dependence on Vibativ for growth is concerning." (1/3/2017)
Leerink Swann analysts commented, "We reiterate our Outperform rating for Theravance’s stock. Stronger than expected Vibativ sales driven by a combination of new indication and expansion of dedicated sales force. Sales of Vibativ increased by 62% QoQ and 152% YoY apparently driven by the expansion of the sales force from 6 to 50 reps in 4Q15 and the opportunity presented by the expanded label. Mgmt believes the growth in revenue will continue driven by the expansion of accounts and positive physician perception in using Vibativ in difficult to treat patients. Several catalysts in next 12 months could potentially add additional value to the company. As highlighted in our earlier note [LINK], our sum of the parts analysis identified potential 20% and 70% upside by end of 2016 and 2017, respectively." (8/9/2016)
Who owns Theravance Biopharma stock?
Theravance Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.64%), Foundation Asset Management LP (0.98%), Marshall Wace LLP (0.79%), Franklin Resources Inc. (0.73%), Chescapmanager LLC (0.52%) and Royce & Associates LP (0.20%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham.
Who sold Theravance Biopharma stock? Who is selling Theravance Biopharma stock?
Theravance Biopharma's stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP. Company insiders that have sold Theravance Biopharma stock in the last year include Bradford J Shafer and Brett K Haumann.
Who bought Theravance Biopharma stock? Who is buying Theravance Biopharma stock?
Theravance Biopharma's stock was acquired by a variety of institutional investors in the last quarter, including Foundation Asset Management LP, Franklin Resources Inc., Marshall Wace LLP, Chescapmanager LLC, State Street Corp, Two Sigma Investments LP, Russell Investments Group Ltd. and Old West Investment Management LLC. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham.
How do I buy Theravance Biopharma stock?
Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Theravance Biopharma stock cost?
One share of Theravance Biopharma stock can currently be purchased for approximately $33.78.